

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number  
**WO 02/45709 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/05**,  
47/14, A61P 23/00, 23/02

(74) Agent: **KASBEKAR, Madhav, Gajanan**; 48/3, Madhavi  
Sah-Nivas, 277, Mogul Lane, Mahim, 400 016 Mumbai  
(IN).

(21) International Application Number: PCT/IN01/00213

(22) International Filing Date: 5 December 2001 (05.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
1106/MUM/2000 7 December 2000 (07.12.2000) IN

(71) Applicant (*for all designated States except US*): **BHARAT  
SERUMS & VACCINES LTD.** [IN/IN]; Road No. 27,  
Wagle Estate, 400 604 Thane, Maharashtra (IN).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PAI, Srikanth**,  
**Annappa** [IN/IN]; Bharat Serums & Vaccines Ltd., Road  
No. 27, Wagle Estate, 400 604 Thane (IN). **RIVANKAR**,  
**Sangeeta**, **Hanurmesh** [IN/IN]; Bharat Serums & Vac-  
cines Ltd., Road No. 27, Wagle Estate, 400 604 Thane  
(IN). **KOCHAREKAR, Shilpa**, **Sudhakar** [IN/IN];  
204/A, Rachna Niraj Co-op. Hsg. Society, Tilak Road,  
Near Nakhwa High School, Kopri, 400603 Thane (West)  
(IN).

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: CLEAR PROPOFOL COMPOSITIONS

(57) Abstract: The present invention relates to a stable clear sterile aqueous composition of Propofol suitable for parenteral admin-  
istration and a process for making the same. The composition comprises Propofol, TPGS and water. The composition of present  
invention gives clear product suitable for parenteral administration overcoming the disadvantages of emulsion formulation. The ratio  
of propofol to TPGS is at least 1: 10 (by wt.) and the content of TPGS is from 1 to 20% w/v in the composition. The composition  
is rendered sterile by end autoclaving.

WO 02/45709 A1

## CLEAR, STABLE PROPOFOL COMPOSITIONS

### Field of Invention

This invention relates to a process for preparation of a clear, sterile anaesthetic composition of Propofol suitable for parenteral administration.

### Background of the Invention :

Propofol (2, 6-diisopropyl phenol) is an intravenous anesthetic agent characterised by a short recovery time. It has the desirable property of rapid onset and offset of the anaesthetic effect following intravenous administration and minimal accumulation on long-term administration.

Propofol even though is a preferred anesthetic agent, has posed a big challenge to the formulators since its invention because of its aqueous insolubility. It was at first formulated as a 1% aqueous solution containing nonionic surfactant Cremophor EL as a solubiliser. However Cremophor EL has been implicated in some adverse reactions when administered intravenously, including anaphylactoid reactions. Subsequently, the anesthetic agent was formulated as an oil-in-water emulsion containing 1% w/v Propofol with 10% w/v soybean oil and 1.2% w/v purified egg phosphatide.

Lipid based emulsions, however, suffer from several limitations which are as follows.

- Improper storage results in poor physical stability.
- On storage produces free fatty acid which is toxic.
- It has potential to cause embolism because of higher oil globule size.
- Causes pain on injection (contains oil in the formulation).
- During administration online microbial filter cannot be used.
- Cannot be visually inspected for foreign particles before administration as the product has milky appearance.

- Can be selectively admixed with only a few injectable products before administration.
- 5 • During administration, strict aseptic techniques must be followed as emulsion system is highly susceptible for bacterial growth.
- During maintenance anaesthesia, infusion tubes require to be changed frequently as the product inside infusion tube may support bacterial growth.
- 10 • Contains Egg lecithin as an emulsifier. Being from an animal source, may produce allergy in some patients.
- 15 • Increases concentration of plasma phospholipid, decreases clearance of triglycerides causing hypertriglyceridemia, hypercholesterolemia.
- Before autoclaving, the product cannot be filtered through 0.22 $\mu$  filter.

20 The inherent limitations of the emulsion formulation as mentioned above could be overcome by eliminating vegetable oil and phospholipids from the formulation. Development of a composition of this type of Propofol formulation (removing vegetable oil and phospholipids) for parenteral administration is possible if Propofol is made soluble in aqueous phase using a solubiliser, as Propofol is an oily liquid, insoluble in

25 water.

WO00/78301 describes an anaesthetic composition for intravenous injection containing Propofol and Poloxamer as the surfactant. Optionally it can contain at least one more surfactant selected from the group consisting of Solutol HS15, Egg lecithin,

30 Labrasol, Polyoxy-10-oleyl ether, Tween, Ethanol and Polyethylene glycol. The composition is prepared in the form of a microemulsion having particle size below 100nm and can be aseptically filtered.

WO01/64187 also describes an similar anaesthetic composition for intravenous injection containing Propofol and Poloxamer. This invention defines the type of polymers that can be used i.e. Propylene oxide portion is at least 2000D while the Ethylene oxide portion is at least 40% w/w. Under formulation stability, the influence of pH and added electrolyte (sodium chloride) on the hydrodynamic radii of micelles has been discussed. However, the stability of the active ingredient Propofol has not been considered in above two patents Poloxamer has been reported to be incompatible with phenols. (Ref. Martindale 32<sup>nd</sup> edition, Pg. 1326) and hence it is doubtful that such compositions would retain propofol activity for a long time.

The main object of the present invention is to develop a clear, stable sterile aqueous composition of Propofol overcoming drawbacks of the existing formulation and also the drawbacks of the prior art.

#### **Summary of the Invention :**

Accordingly the present invention relates to a clear stable anaesthetic composition suitable for parenteral administration comprising Propofol (1mg/ml to 20mg/ml of the composition), d-Alpha Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) keeping the ratio of propofol to TPGS at least 1: 10 (by wt.) and the content of TPGS from 1 to 20 % w/v, in the composition, and water with or without parenterally acceptable conventional additives.

The process of manufacturing the anaesthetic composition of present invention comprises

- a) dissolving TPGS in water to give TPGS solution;
- b) adding propofol under mixing to said TPGS solution to give anaesthetic composition;
- c) said additives if required may be added to water, TPGS solution or anaesthetic composition formed;

- d) making up the volume with water to the desired level of propofol in the anaesthetic composition;
- 5 e) filtering the composition obtained at the end of step (d) through 2 $\mu$  and 0.2 $\mu$  filter;
- f) filling the filtrate obtained at the end of step (e) in containers such as vials, ampoules, plastic containers followed by nitrogen purging and sealing the filled containers;
- 10 g) autoclaving the sealed containers filled with said filtrate.

**Detailed description of embodiments of the Invention :**

15 While developing an anaesthetic composition of Propofol in light of the object set as above, we found that some hydrophobic therapeutic drugs are dissolved in  $\alpha$ -tocopherol, an oily material and then the  $\alpha$ -Tocopherol solution is emulsified using TPGS as emulsifier (Ref: W098/30205). As we intended to avoid oily composition, after lot of experimentation we found that by using sufficiently large quantities of TPGS we can

20 solubilise the anaesthetic hydrophobic propofol in water giving a composition suitable for parenteral administration.

WO98/30205 discloses substantially ethanol-free self-emulsifying drug delivery system. The pharmaceutical compositions of the invention are typically formed by

25 dissolving a therapeutic agent in ethanol to form a therapeutic agent solution. Alpha-tocopherol is then added to the therapeutic agent solution to form an alpha-tocopherol and therapeutic agent solution. Next, the ethanol is removed to form a substantially ethanol-free alpha-tocopherol and therapeutic agent solution. The substantially ethanol free alpha-tocopherol and therapeutic agent solution is blended with and without an aqueous phase

30 incorporating a surfactant to form a pre-emulsion. For intravenous delivery the pre-emulsion is then homogenised to form a fine emulsion.

In this delivery system ethanol is used to dissolve the therapeutic agent and incorporated into large amount of  $\alpha$ -tocopherol which is essential for holding the drug in solution.

TPGS is a water soluble form of alpha-tocopherol prepared by esterifying the acid group of crystalline d-alpha-tocopheryl acid succinate with polyethylene glycol 1000. TPGS is very stable and does not hydrolyze under normal conditions.

10

TPGS melts at 41°C and degrades at temperatures above 199°C. TPGS has a solubility of 20gm% in water at 20°C. TPGS has an HLB value in the region of 15 - 19.

For dissolving TPGS in water, TPGS is required to be added to hot water. The preferred temperature of water could be from 45°C to 100°C.

15

TPGS does not degrade if exposed to oxygen, heat, light or oxidising agents. It is unstable to alkali.

While preparing the composition of our present invention, after lot of experimentation we found that an oil soluble anaesthetic agent Propofol can be solubilised in water with the help of TPGS, without using any tocopherol or any oily phase if we use higher amounts of TPGS to give a solubilised product containing Propofol

20  
25

The composition of present invention gives a stable product when stored under controlled conditions of temperature i.e. under refrigeration.

The Propofol content of the composition of present invention is from about 1mg/ml to about 20mg/ml, preferably from about 2mg/ml to about 20mg/ml, more preferably 10mg/ml.

30

The TPGS content of the composition of present invention is from about 10mg/ml to about 200mg/ml, preferably from about 100mg/ml to about 150mg/ml, more preferably  
5 100mg/ml.

The present invention gives a clear stable, sterile aqueous composition suitable for parenteral administration without addition of any conventional additives.

10 However, in another embodiment of the invention addition of conventional additives if required by parenteral dosage form may be added to the aqueous solution at any stage of preparation.

Parenterally acceptable conventional additives when added are selected from a  
15 group of additives such as buffers, tonicity modifying agents, preservatives, antioxidants at conventional usage levels.

Any of the parenterally used buffer can be used in the composition of present invention which is selected from a group of buffers such as phosphate buffer, glycine  
20 buffer, citrate buffer or a mixture thereof. Phosphate buffer is preferred whenever buffer is used. Phosphate buffers with different compositions of sodium dihydrogen phosphate, disodium hydrogen phosphate, phosphoric acid, sodium hydroxide can be used to give a desired pH to the composition. A pH range of 4.0 - 8.0 of the final composition is preferred.

25 The composition of present invention can also contain tonicity modifying agent to make the composition isotonic with the blood. The tonicity modifying agent is selected from a group of parenterally acceptable compounds such as dextrose, sodium chloride, mannitol, sorbitol, glycerin, propylene glycol or a mixture thereof. Glycerin is  
30 particularly preferred as tonicity modifying agent at a concentration of 2 - 3% w/v of the composition when used. 2.25% w/v of the glycerin is more preferred in the final composition.

Preservatives when used in the composition of present invention are selected from a group of parenterally acceptable compounds such as disodium edetate, benzyl alcohol, sodium benzoate or a mixture thereof. Disodium edetate is the preferred preservative in a concentration range of 0.0025% to 0.01% w/v of the composition when used.

The composition of present invention can also contain antioxidants which are selected from a group of parenterally acceptable compounds such as ascorbyl-6 palmitate, ascorbic acid, salts of ascorbic acid. One of the advantages of TPGS is that it by itself acts as an antioxidising agent and additional antioxidants may not be necessary.

Various modifications, additions will become apparent to those skilled in the art in light of the foregoing disclosures without departing from the spirit and scope of the disclosed invention. Therefore it is to be understood that the invention is not limited to the disclosed embodiments, but may be practised within the full scope of claims appended herewith.

#### **Examples :**

The invention will now be illustrated by way of examples. The examples are by way of illustration only and in no way restrict the scope of the invention.

All the raw materials used in this example were of parenteral grade. Equipments used were of conventional nature. Entire processing was done in an area with a controlled environment. Nitrogen cover was provided while processing the batch.

The following materials were used in the Examples

- a) Propofol was procured from Cilag AG
- b) TPGS complying with United States National Formulary (USNF) specification was procured from M/s. Eastman Chemical Ltd.
- c) Water complying with "Water for Injection" specifications of Indian Pharmacopoeia was used.
- d) Glycerin complying with specifications of Indian Pharmacopoeia was used.



- e) Disodium edetate complying with specifications of Indian Pharmacopoeia was used.
- 5 f) Potassium dihydrogen phosphate complying with specifications of USNF was used.
- g) Disodium hydrogen phosphate complying with specifications of Indian Pharmacopoeia was used.
- h) Diprivan - Propofol Emulsion (10mg/ml) available commercially was used.

10

**Example I :**

TPGS was melted and 20gms of molten TPGS was added to boiling water (170ml). Stirred till TPGS got dissolved completely. Propofol (2gms) was added to TPGS solution under stirring. The product was stirred till a clear solution was obtained.

- 15 Volume was made upto 200ml with water. Filtration was carried out using 2 $\mu$  prefilter and 0.22 $\mu$  membrane filter. The product was filled into sterile pyrogen free glass vials under nitrogen cover under laminar flow. The vials were closed using flurotec rubber stoppers and sealed using aluminium seals. The filled and sealed vials were autoclaved at 121°C for 20 minutes.

20

**STABILITY DATA OF PRODUCT OF EXAMPLE I UNDER  
RECOMMENDED STORAGE CONDITIONS of 2 - 8°C**

| PERIOD   | APPEARANCE                      | PROPOFOL CONTENT |
|----------|---------------------------------|------------------|
| Initial  | Clear slightly yellowish liquid | 101.63%          |
| 6 Months | Clear slightly yellowish liquid | 100.42%          |
| 9 Months | Clear slightly yellowish liquid | 99.47%           |

- 25 The above stability data indicates that the product prepared in Example I is suitable for commercial marketing.

**Example II :**

- 30 Example II was same as Example I except that Glycerin (4.5gms) was added after solubilising Propofol.

**Example III :**

Example III was same as Example II except that Disodium Edetate (0.011gms) was dissolved in boiling water before addition of TPGS.

**Example IV :**

Example IV was same as Example I except that Phosphate buffer of pH 5.5 was used in place of water.

Phosphate buffer of pH 5.5 was prepared by mixing 96.4ml of "Solution I" with 3.6ml of "Solution II".

- 1) **Solution I** - Dissolve 13.61gm of Potassium dihydrogen phosphate in sufficient water to produce 1000ml.
- 2) **Solution II** - Dissolve 35.81gm of Disodium hydrogen phosphate in sufficient water to produce 1000ml.

**Example V**

Same as Example I except that 16gms of TPGS was used instead of 20gms. The product obtained was hazy indicating incomplete solubilisation of propofol.

**Example VI**

Propofol composition prepared in Example I was subjected to in-vivo toxicity studies in mice.

**Single dose toxicity study in mice****Material and method**

**Test System :** Female Swiss albino mice in the weight range of 20-22 gm were obtained from the animal house of Bharat Serums & Vaccines Ltd (BSVL) and employed for the study. The animals were provided with standard chow and Aquaguard™ water, *ad libitum*.

**Test Material :** Propofol composition (10 mg/ml) prepared in Example I, was administered intravenously.

5

**Comparative material :** Diprivan - Propofol emulsion (10mg/ml) available commercially was administered intravenously.

10 All animals (8 from each group) were observed for signs of clinical toxicity if any and for mortality for a period of 72 hours. The percent mortality was calculated for all the doses. The results are given in the following table.

| Dose<br>(mg/kg body wt.) | % mortality in sample of<br>Example I | % mortality in Diprivan<br>sample |
|--------------------------|---------------------------------------|-----------------------------------|
| 35                       | 0                                     | 0                                 |
| 40                       | 25                                    | 25                                |
| 45                       | 37.5                                  | 37.5                              |
| 50                       | 50                                    | 50                                |

**Observations :**

15 The groups which received Propofol composition from Example I showed similar signs of toxicity as compared to the group which received Diprivan.

**Example VII**

20 Propofol composition prepared in Example I was subjected to efficacy study in mice.

**Material and method**

25 **Test System :** Female Swiss albino mice in the weight range of 20-22 gm were obtained from the animal house of Bharat Serums & Vaccines Ltd (BSVL) and employed for the study. The animals were provided with standard chow and Aquaguard™ water, *ad libitum*.

**Test Material** : Propofol composition (10 mg/ml) prepared in Example I, was administered intravenously at a dose of 35mg/kg.

5

**Comparative material** : Diprivan - Propofol emulsion (10mg/ml) available commercially was administered intravenously at a dose of 35mg/kg.

All the animals (8 from each group) were observed for the time taken to go into anaesthesia and the time taken to come out of anaesthesia. The observations are as follows :

| AVERAGE INDUCTION TIME |          | AVERAGE RECOVERY TIME |          |
|------------------------|----------|-----------------------|----------|
| Example I              | Diprivan | Example I             | Diprivan |
| 4.2 sec.               | 4.1 sec. | 8.6 min.              | 7.9 min. |

The stability studies, toxicity studies and efficacy studies on Example I demonstrated that the composition of present invention is stable overcoming all the disadvantages of the emulsion formulation discussed earlier and comparable to Diprivan in toxicity and efficacy.

#### **Advantages of the present invention :**

The present invention gives a clear sterile anaesthetic composition that overcomes the disadvantages of emulsion formulation discussed earlier and gives a composition which has many advantages some of which are as follows:

- i. The composition is clear, can be visually inspected before administration and can be administered with the use of on-line microbial filter.
- ii. The composition does not contain phospholipids. Hence plasma phospholipids are unaffected on parenteral administration of the composition.
- iii. The composition does not cause any change in triglyceride clearance
- iv. The composition can be mixed with any of the commonly used diluents before administration.

30

### CLAIMS

1. A clear stable anaesthetic composition suitable for parenteral administration  
5 comprising Propofol (1mg/ml to 20mg/ml of the composition), d-Alpha  
Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) keeping the ratio of  
propofol to TPGS at least 1: 10 (by wt.) and the content of TPGS from 1 to 20  
% w/v in the composition, and water; with or without parenterally acceptable  
additives.  
10
2. A clear stable anaesthetic composition suitable for parenteral administration as  
claimed in claim 1 wherein the content of Propofol is about 10mg/ml of the  
composition.
- 15 3. A clear stable anaesthetic composition suitable for parenteral administration as  
claimed in any of claims 1 or 2 wherein the content of TPGS is from about  
100mg/ml to about 150mg/ml of the composition
4. A clear stable anaesthetic composition suitable for parenteral administration as  
20 claimed in any of claims 1 to 3 wherein the parenterally acceptable additives are  
selected from group of additives such as buffers, tonicity modifying agents,  
preservatives, antioxidants.
5. A clear stable anaesthetic composition suitable for parenteral administration as  
25 claimed in any of claims 1 to 4 wherein the buffer used is selected from a group of  
parenterally acceptable buffers such as phosphate buffer, glycine buffer, citrate  
buffer or a mixture thereof.
6. A clear stable anaesthetic composition suitable for parenteral administration as  
30 claimed in any of claims 1 to 5 wherein the tonicity modifying agent used is  
selected from a group of parenterally acceptable compounds such as dextrose,  
sodium chloride, mannitol, sorbitol, glycerin, propylene glycol or a mixture  
thereof.

- 5 7. A clear stable anaesthetic composition suitable for parenteral administration as claimed in any of claims 1 to 6 wherein the tonicity modifying agent used is glycerin.
- 10 8. A clear stable anaesthetic composition suitable for parenteral administration as claimed in any of claims 1 to 7 wherein the tonicity modifying agent used is propylene glycol.
- 15 9. A clear stable anaesthetic composition suitable for parenteral administration as claimed in any of claims 1 to 8 wherein the preservative used is selected from a group of parenterally acceptable compounds such as disodium edetate, benzyl alcohol, sodium benzoate or a mixture thereof.
- 20 10. A process for preparation of clear stable anaesthetic composition suitable for parenteral administration as claimed in any of claims 1 to 9, comprising
- a) dissolving TPGS in water to give TPGS solution;
  - b) adding propofol under mixing to said TPGS solution to give anaesthetic composition;
  - 25 c) said additives if required may be added to water, TPGS solution or anaesthetic composition formed;
  - d) making up the volume with water to the desired level of propofol in the anaesthetic composition;
  - 30 e) filtering the composition obtained at the end of step (d) through 2 $\mu$  and 0.2 $\mu$  filter;

- 5           f) filling the filtrate obtained at the end of step (e) in containers such as vials, ampoules, plastic containers followed by nitrogen purging and sealing the filled containers;
- g) autoclaving the sealed containers filled with said filtrate.
- 10       11.   A clear stable anaesthetic composition suitable for parenteral administration as claimed in any of claims 1-9 prepared by the process as claimed in claim 10.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IN 01/00213

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/05 A61K47/14 A61P23/00 A61P23/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| A          | WO 98 30205 A (SONUS PHARMA INC)<br>16 July 1998 (1998-07-16)<br>abstract<br>page 8, line 18 - line 25<br>page 11, line 19 - line 25<br>claims 1-23<br>--- | 1-11                  |
| A          | WO 99 39696 A (GENSIA SICOR INC)<br>12 August 1999 (1999-08-12)<br>abstract<br>claims 1-49<br>---  | 1-11                  |
| A          | WO 00 44369 A (KURANI SHASHIKANT PRABHUDAS<br>;PATEL DINESH SHANTILAL (IN))<br>3 August 2000 (2000-08-03)<br>abstract<br>claims 1-11<br>---                | 1-11                  |
|            | ---<br>-/--  |                       |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

8 May 2002

Date of mailing of the international search report

16/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Taylor, G.M.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IN 01/00213

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| A          | US 5 714 520 A (JONES CHRISTOPHER BUCHAN<br>ET AL) 3 February 1998 (1998-02-03)<br>abstract<br>claims 1-39<br>----  | 1-11                  |
| E          | WO 01 97796 A (KOCHAREKAR SHILPA ;RIVANKAR<br>SANGEETA (IN); PAI SRIKANTH (IN); BHAR)<br>27 December 2001 (2001-12-27)<br>abstract<br>claims 1-34<br>----                             | 1-11                  |
| P,A        | WO 00 78301 A (KUHNIL PHARM CO LTD ;CHO<br>HOON (KR); JIN JI YOUNG (KR); LEE HYUK KO)<br>28 December 2000 (2000-12-28)<br>cited in the application<br>abstract<br>claims 1-9<br>----- | 1-11                  |

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No

PCT/IN 01/00213

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9830205                                | A | 16-07-1998          | EP 0981328 A1              | 01-03-2000          |
|   |   |                     | JP 2001508445 T            | 26-06-2001          |
|   |   |                     | WO 9830205 A1              | 16-07-1998          |
|   |   |                     | AU 5731498 A               | 03-08-1998          |
|   |   |                     | ZA 9800098 A               | 08-07-1998          |
| WO 9939696                                | A | 12-08-1999          | AU 2599199 A               | 23-08-1999          |
|   |   |                     | BR 9907832 A               | 31-10-2000          |
|   |   |                     | CA 2319810 A1              | 12-08-1999          |
|   |   |                     | EP 1052975 A1              | 22-11-2000          |
|   |   |                     | JP 2002502811 T            | 29-01-2002          |
|   |   |                     | WO 9939696 A1              | 12-08-1999          |
|   |   |                     | US 6147122 A               | 14-11-2000          |
| WO 0044369                                | A | 03-08-2000          | AU 1888700 A               | 18-08-2000          |
|   |   |                     | CN 1334725 T               | 06-02-2002          |
|   |   |                     | EP 1143962 A1              | 17-10-2001          |
|   |   |                     | WO 0044369 A1              | 03-08-2000          |
|   |   |                     | US 6071974 A               | 06-06-2000          |
| US 5714520                                | A | 03-02-1998          | DE 19509828 A1             | 19-09-1996          |
|   |   |                     | FR 2731617 A1              | 20-09-1996          |
|   |   |                     | WO 9629064 A1              | 26-09-1996          |
|   |   |                     | GB 2298789 A ,B            | 18-09-1996          |
|   |   |                     | IT MI950529 A1             | 22-09-1995          |
|   |   |                     | US 5908869 A               | 01-06-1999          |
|   |   |                     | US 5731355 A               | 24-03-1998          |
|   |   |                     | US 5731356 A               | 24-03-1998          |
| WO 0197796                                | A | 27-12-2001          | WO 0197796 A1              | 27-12-2001          |
| WO 0078301                                | A | 28-12-2000          | AU 5574200 A               | 09-01-2001          |
|   |   |                     | EP 1202719 A1              | 08-05-2002          |
|   |   |                     | WO 0078301 A1              | 28-12-2000          |